Emerging in the landscape of excess body fat therapy, retatrutide presents a distinct strategy. Different from many current medications, retatrutide functions as a dual agonist, at once targeting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This concurrent stimulation fosters various advanta